Monitor TAPI's performance in upcoming Teva quarterly reports for any operational changes under new leadership. The appointment is routine and unlikely to affect Teva's near-term stock price.
Price Chart
Executive Summary
TAPI, a subsidiary of Teva Pharmaceutical Industries, appointed Serge Rogasik as its new CEO. Rogasik brings over 25 years of experience in specialty ingredients and life sciences, with a track record of transforming private equity-backed companies. The appointment is a routine leadership change at a subsidiary level and does not provide any financial data or guidance.
Key Facts
- Serge Rogasik appointed CEO of TAPI, Teva's API and CDMO subsidiary.
- Rogasik previously led Kensing, a specialty ingredients company owned by One Rock Capital Partners.
- TAPI has 4,100 employees, 13 manufacturing sites, and supplies 350+ active ingredients globally.
- No financial figures, guidance, or material business changes were disclosed in the press release.
Financial Impact
No financial impact disclosed; routine leadership change at a subsidiary.
Risk Factors
- No immediate risks identified; leadership changes at subsidiaries rarely move the parent company's stock.
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3372408 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | Press Release | $39.22 | awaiting T+60 | — | $40.38 (+2.97%) |
Oct 15, 2026 11d ago | Institutional Cluster | $41.11 | awaiting T+60 | — | $40.38 (+1.76%) |
Oct 8, 2026 18d ago | 3 | $41.10 | awaiting T+60 | — | $40.38 (−1.74%) |
Oct 2, 2026 25d ago | Press Release | $39.53 | awaiting T+60 | — | $40.38 (+2.16%) |
Oct 2, 2026 25d ago | Press Release | $39.53 | awaiting T+60 | — | $40.38 (+2.16%) |
Sep 30, 2026 26d ago | Press Release | $39.31 | awaiting T+60 | — | $40.38 (+2.73%) |
Sep 28, 2026 28d ago | Press Release | $39.81 | awaiting T+60 | — | $40.38 (+1.44%) |
Sep 23, 2026 4w ago | Press Release | $40.22 | awaiting T+60 | — | $40.38 (+0.41%) |
Sep 23, 2026 4w ago | Press Release | $40.22 | awaiting T+60 | — | $40.38 (+0.41%) |
Sep 22, 2026 4w ago | Insider Cluster | $39.01 | awaiting T+60 | — | $40.38 (−3.52%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers